POPDC2 a novel susceptibility gene for conduction disorders.


Journal

Journal of molecular and cellular cardiology
ISSN: 1095-8584
Titre abrégé: J Mol Cell Cardiol
Pays: England
ID NLM: 0262322

Informations de publication

Date de publication:
08 2020
Historique:
received: 05 02 2020
revised: 22 05 2020
accepted: 09 06 2020
pubmed: 15 6 2020
medline: 13 8 2021
entrez: 15 6 2020
Statut: ppublish

Résumé

Despite recent progress in the understanding of cardiac ion channel function and its role in inherited forms of ventricular arrhythmias, the molecular basis of cardiac conduction disorders often remains unresolved. We aimed to elucidate the genetic background of familial atrioventricular block (AVB) using a whole exome sequencing (WES) approach. In monozygotic twins with a third-degree AVB and in another, unrelated family with first-degree AVB, we identified a heterozygous nonsense mutation in the POPDC2 gene causing a premature stop at position 188 (POPDC2

Identifiants

pubmed: 32535041
pii: S0022-2828(20)30214-5
doi: 10.1016/j.yjmcc.2020.06.005
pii:
doi:

Substances chimiques

Cell Adhesion Molecules 0
Muscle Proteins 0
POPDC2 protein, human 0
Popdc2 protein, mouse 0
Potassium Channels, Tandem Pore Domain 0
potassium channel protein TREK-1 0
RNA 63231-63-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

74-83

Subventions

Organisme : British Heart Foundation
ID : AA/18/2/34218
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/J010383/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/14/46/30911
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/19/13/34247
Pays : United Kingdom

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest L.Fa has received institutional research grants from European Union, British Heart Foundation, Medical Research Council (UK), DFG and Gilead. L.Fa is listed as inventor on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783).

Auteurs

Susanne Rinné (S)

Institute for Physiology and Pathophysiology, Vegetative Physiology and Marburg Center for Mind, Brain and Behavior MCMBB, Philipps-University of Marburg, Marburg, Germany.

Beatriz Ortiz-Bonnin (B)

Institute for Physiology and Pathophysiology, Vegetative Physiology and Marburg Center for Mind, Brain and Behavior MCMBB, Philipps-University of Marburg, Marburg, Germany.

Birgit Stallmeyer (B)

Institute for Genetics of Heart Diseases (IfGH), University Hospital Münster, Münster, Germany.

Aytug K Kiper (AK)

Institute for Physiology and Pathophysiology, Vegetative Physiology and Marburg Center for Mind, Brain and Behavior MCMBB, Philipps-University of Marburg, Marburg, Germany.

Lisa Fortmüller (L)

Institute of Human Genetics, Department of Genetic Epidemiology, University Hospital Münster, Münster, Germany; Cardiology II-Electrophysiology, University Hospital Münster, Münster, Germany.

Roland F R Schindler (RFR)

National Heart and Lung Institute, Imperial College London, London, United Kingdom.

Ursula Herbort-Brand (U)

National Heart and Lung Institute, Imperial College London, London, United Kingdom.

Nashitha S Kabir (NS)

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom.

Sven Dittmann (S)

Institute for Genetics of Heart Diseases (IfGH), University Hospital Münster, Münster, Germany.

Corinna Friedrich (C)

Institute for Genetics of Heart Diseases (IfGH), University Hospital Münster, Münster, Germany.

Sven Zumhagen (S)

Institute for Genetics of Heart Diseases (IfGH), University Hospital Münster, Münster, Germany.

Francesca Gualandi (F)

Unit of Medical Genetics, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

Rita Selvatici (R)

Unit of Medical Genetics, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

Claudio Rapezzi (C)

Cardiovascular Center, University of Ferrara, Ferrara and Maria Cecilia Hospital, GVM Care & Research, Cotignola (RA), Italy.

Eloisa Arbustini (E)

Policlinico S. Matteo, Pavia, Italy.

Alessandra Ferlini (A)

Unit of Medical Genetics, Department of Medical Sciences, University of Ferrara, Ferrara, Italy; Dubowitz Neuromuscular Centre, Developmental Neuroscience Programme, University College of London, Institute of Child Health, London, United Kingdom.

Larissa Fabritz (L)

Cardiology II-Electrophysiology, University Hospital Münster, Münster, Germany; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; Department of Cardiology, University Hospital Birmingham, Birmingham, United Kingdom.

Eric Schulze-Bahr (E)

Institute for Genetics of Heart Diseases (IfGH), University Hospital Münster, Münster, Germany.

Thomas Brand (T)

National Heart and Lung Institute, Imperial College London, London, United Kingdom.

Niels Decher (N)

Institute for Physiology and Pathophysiology, Vegetative Physiology and Marburg Center for Mind, Brain and Behavior MCMBB, Philipps-University of Marburg, Marburg, Germany. Electronic address: decher@staff.uni-marburg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH